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Covalent conjugation of immune-stimulatory compounds to protein antigens is a potential means to self-
adjuvant non-replicating subunit vaccines. Previously, it was demonstrated that covalent coupling of a
Toll-like receptor (TLR) ligand to the exterior HIV-1 envelope glycoprotein, gp120, enhanced its
immunogenicity. However, the consequences of chemical conjugation to gp120 on broadly neutralizing
antibody (bNAb) epitopes were so far not examined. Here, we conjugated a TLR7/8 ligand to lysine
residues on gp120 using NHS-PEO8-maleimide linkers and investigated if this affected Ab recognition of
the CD4 binding site (CD4bs), a highly conserved target for bNAbs. We demonstrate that the recognition
of the CD4bs was reduced following coupling, especially at a higher coupling ratio. These results have
implications for the coupling of ligands to vaccine antigens where elicitation of humoral immune
responses to speciﬁc neutralizing determinants is desired.
& 2013 Elsevier Inc. All rights reserved.Introduction
Activation of the innate immune system is critical for the
induction of strong adaptive immune responses against invading
pathogens. In part, this is achieved by recognition of molecules
that are directly or indirectly associated with the infection by
specialized cellular receptors, leading to intra- and intercellular
signaling cascades that promote inﬂammatory responses and
immune activation. A plethora of pattern recognition receptors
(PRRs) were described in the past decades, including Toll-like
receptors (TLRs), RIG-I-like receptors (RLRs) and inﬂammasome-
associated molecules (Akira et al., 2001; Blasius and Beutler, 2010;
Henao-Mejia et al., 2012; Jacobs and Damania, 2012; Kawai and
Akira, 2010; Loo and Gale, 2011; Rathinam et al., 2012). Of the
TLRs, several sense single-stranded or double-stranded RNA or
DNA to alert the host of an invading pathogen. The increasedll rights reserved.
IV/AIDS Vaccine Immunology
itute, La Jolla, CA 92037, USA.
stam).deﬁnition of PRRs and their downstream signaling pathways has
encouraged the development of molecular adjuvants that target
these, such as synthetic analogues of TLR ligands (reviewed in
(Akira et al., 2001; Carter and Reed, 2010; Coffman et al., 2010;
Guy, 2007; Lore and Karlsson Hedestam, 2009; Pulendran, 2004)).
Studies in mice and non-human primates demonstrate that
TLR ligands, when used together with puriﬁed protein antigens,
stimulate enhanced humoral and cellular immune responses
(Huleatt et al., 2007; Jackson et al., 2004; Tewari et al., 2010;
Weiner et al., 1997; Wille-Reece et al., 2005a). Dendritic cells (DCs)
are the primary target cells for priming naïve T cells. However,
other antigen-presenting cells such as B cells are also activated by
some TLR ligands, in particular by TLR7/8/9 ligands (Lanzavecchia
and Sallusto, 2007), which may inﬂuence humoral immunity. The
possibility to directly conjugate TLR ligands to protein-based
vaccines to augment both cellular and humoral immune responses
therefore represents an attractive approach to vaccine design.
However, the consequences of such chemical modiﬁcations for
the integrity of antigenic sites on target proteins that may be
critical for the elicitation of broadly neutralizing antibodies are
currently not well deﬁned.
Here, we examined the effects of chemically cross-linking a
synthetic TLR7/8 ligand to surface-exposed lysine residues on the
Fig. 1. Molecular surface of the gp120 core and schematic of the coupling
reaction. (A). The gp120 surface in light blue with solvent accessible lysine residues
in dark blue. Left, the primary receptor CD4 binding site is in yellow and is also the
target for broadly neutralizing antibodies. Right, the surface of the core rotated 180
degrees from the CD4 binding site orientation. (B) The N-hydroxysuccinimde (NHS)
ester of the NHS-PEO8 maleimide linker reacts with primary amine side chain of
the lysines residues on the gp120 surface and the N-terminus. Excess linker is
removed by a desalting column. The maleimide group on the gp120-linker
intermediate reacts with a thiol group present on the TLR7/8 ligand, which then
achieves covalent attachment of the TLR ligand to gp120. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
Y. Feng et al. / Virology 446 (2013) 56–65 57external subunit of the HIV-1 envelope glycoprotein (Env), gp120.
We selected HIV-1 gp120 as a suitable antigen to test this concept
since the antigenic properties of this antigen are well described
and because alternative approaches for HIV-1 Env-based vaccine
design are critically needed to elicit effective Ab responses,
including bNAbs (Burton et al., 2004; Karlsson Hedestam et al.,
2008; Mascola and Monteﬁori, 2010). Of the nucleic acid-based
TLR ligands, we chose a TLR7/8 ligand for these studies as both
myeloid DCs (MDCs) and plasmacytoid DC (PDCs) express TLR7 or
TLR8, which upon activation mediate antigen presentation and
production of innate cytokines critical for enhancing T and B cell
responses (Lore et al., 2003). Importantly, since B cells also express
TLR7/8 (Bourke et al., 2003; Bekeredjian-Ding et al., 2005; Douagi
et al., 2009) antigens that are covalently conjugated to such
ligands have the potential to activate B cells both directly and
indirectly via DCs. This makes TLR7/8 ligands particularly well
suited for the studies performed here. Previous studies demon-
strate that direct conjugation with this TLR ligand effectively
enhance immune responses to another protein-based antigen,
HIV-1 Gag, as assessed in both mice and non-human primates
(Wille-Reece et al., 2005a, 2006, 2005b).
In the current study, we demonstrate that it was possible to
control the amount of ligand that was covalently attached to the
gp120 surface lysines by varying the ratio of linker to gp120 in the
coupling reaction. We found that an increased ratio of TLR7/8
ligand to gp120 led to more effective in vitro activation of PDCs to
produce IFN-alpha. However, high levels of coupling abrogated the
binding by several Env ligands tested, including several bNAbs
recognizing the conserved primary receptor binding site (CD4bs),
a critical neutralizing determinant and vaccine target on Env. We
therefore attempted to alter this outcome by structure-guided,
conservative lysine to arginine substitutions on residues proximal
to the CD4 binding region of gp120. However, these structure-
based alterations did not preserve recognition of these epitopes
following coupling.
Collectively, the data presented in this study demonstrate a
hitherto unappreciated consequence of cross-linking ligands to
HIV-1 Env, highlighting the need to carefully evaluate B cell
recognition of conformational epitopes on antigens modiﬁed by
this approach before attempting to elicit effective Ab responses
in vivo.Results
Cross-linking and biochemical characterization of HIV-1 gp120:
Cross-linker and TLR7/8 ligand conjugates
In the present study, we used heterobi-functional NHS-PEO8-
maleimide linkers to conjugate a TLR7/8 ligand to puriﬁed,
monomeric gp120 derived from the HIV-1 strain, YU2. We
attempted as well cross-linker modiﬁcation of soluble YU2
gp140 trimers, however this treatment resulted in very high
molecular weight oligomers, which we deemed unsuitable immu-
nogens (not shown). For gp120, we adjusted the reaction condi-
tions so that different coupling ratios of cross-linker or TLR ligand
to gp120 were obtained and we investigated the biochemical and
biological consequence of these different coupling conditions. YU2
gp120 contains 30 lysines on its molecular surface with 20 of these
charged residues located in the gp120 core-region (Fig. 1A),
5 residues in variable regions 1, 2 and 3 (V1V2V3) and 5 additional
in the N and C-terminal conserved regions (not shown). The
primary amines of each solvent-exposed lysine residue (and the
N-terminus) are potentially highly reactive with N-hydroxysucci-
nimide (NHS) esters, leading to the formation of an amide bond.
Use of NHS esters is a common method to form covalent bondsbetween a protein and a small molecule of choice, either directly
or indirectly via a NHS-containing linker intermediate. To cova-
lently link a sulfhydryl-containing TLR7/8 ligand to gp120, we ﬁrst
produced gp120-maleimide intermediates by reacting gp120 with
different molar ratios of an amine-to-sulfhydryl linker (NHS-PEO8-
maleimide) (Fig. 1B). The resulting gp120-maleimide intermediate
was then incubated with an excess of sulfhydryl-containing TLR7/8
ligand to allow cross linking of the active maleimide with the reactive
sulfhydryl on the ligand (Fig. 1B).
To investigate the approximate coupling stoichiometries
achieved following conjugation of the cross-linker and the
TLR7/8 ligand to gp120, we performed analysis by SDS-PAGE and
size exclusion chromatography. Accordingly, we ﬁrst examined the
apparent molecular weight (MW) of gp120 and the cross-linked
gp120 conjugates on reducing gels. Since gp120 is a relatively
large, heavily glycosylated protein, with N-linked carbohydrate
comprising roughly 50% of its molecular mass, we performed gel
analysis on both untreated and deglycosylated gp120 (Fig. 2A, left
panel). We reasoned that the lower MW bands following degly-
cosylation of gp120 might enable us to better estimate the average
cross-linker conjugation levels per gp120 molecule. To generate
deglycosylated gp120, we ﬁrst expressed the protein from 293
cells either in the presence of swainsonine, or from GnTI- 293S
cells. Both these treatments of the cells theoretically render all
N-linked glycans on the recombinant gp120 as forms of high
mannose and thereby sensitive to both Endo H and PNGase
digestion. For the MW estimates, we were unable to fully degly-
cosylate full-length gp120 by the relatively mild Endo H reaction
conditions (not shown) so we performed deglycosylation with
PNGase under denaturing conditions. Following PNGase digestion,
we estimated the MW of untreated and cross-linked gp120 using
the center of the Coomassie-blue stained glycoprotein bands on
the gel. A representative analysis of three independent digestions
Fig. 2. Analysis of gp120-linker intermediates and gp120-TLR7/8 conjugates at different coupling ratios. (A) YU2 gp120, produced in 293S cells was reacted with
different molar ratios of NHS-PEO8-maleimide linker. MW standards are shown (left panel). The gp120:cross-linker intermediates were resolved by SDS-PAGE before
(middle panel) or after deglycosylation with PNGase (right panel). (B) Protein standards were used to estimate MW shifts based upon migration distance in the gel. On this
gel image, the measurements from the origin of the wells to the center of each band are shown in red using the gel analysis software Quantity Ones (Bio-Rad Laboratories,
Inc). Right top, the equation of the calibration curve generated by plotting log MW versus relative migration distances (Rf) of the standards in the gel is shown. Red dots
indicate the gp120 values with or without cross-linker plotted onto the curve. The change in apparent MW generated by each reaction condition was determined using the
calibration curve. Right bottom, approximate apparent MW shift differentials and cross-linker-to-gp120 stoichiometries are shown. (C) Following conjugation, the proteins
were puriﬁed by SEC. The FPLC proﬁles of gp120 (blue), gp120-Lo (brown, gp120-TLR7/8 at coupling ratio 1:20) and gp120-Hi (red, gp120-TLR7/8 at coupling ratio 1:120) are
shown. (D) By collecting and concentrating approximately 75% of the latter portion of the gp120-containing fractions, we could exclude the majority of gp120 dimers, as can
be seen on the post-FPLC gel image. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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standards, we derived a graph plotted from the log MW versus
relative migration distance of the gp120 bands [Rf¼(protein
migration)/(migration of the 38 kDa band from the MW stan-
dards)] (Fig. 2B). The approximate apparent MW of the PNGase-
digested gp120 and the gp120-maleimide intermediates was
calculated by interpolation using this graph. By averaging values
derived from the three independent gel runs, the difference in
MW between unconjugated gp120, and the gp120-maleimide
intermediates at different ratios of 1:5, 1:20 and 1:120, was
determined to be 9.0, 9.7 and 14.5 kDa, respectively, correspond-
ing to the coupling of 13, 14 and 21 NHS-PEO8-maleimide linkers
(MW¼0.69 kDa) to each molecule of gp120, on average (Fig. 2B).
We observed that, although untreated gp120 was reduced to a
tight protein band consistent with full deglycosylation by PNGase,
the bands of the cross-linked gp120 were broader. This is likely
due to heterogeneity of cross-linker coupling to the population of
gp120 molecules in the reaction mixture. Consistent with this
interpretation, when estimating the number of cross-linker mole-
cules per gp120 using both the front and trailing edge of the
protein:adduct bands on the gel shown in Fig. 2B, we derived
ranges that did not exceed the limit of 30 conjugated lysines pergp120, even at the highest cross-linker concentration. For the
NHS-PEO8-maleimide linkers, the value were 13 (range 5–19), 14
(range 5–19), and 21 (13–27) crosslinkers per gp120, respectively.
Besides the predominant monomeric TLR-ligand-gp120 spe-
cies, we also observed a band with a higher MW in the gel lanes
loaded with gp120-maleimide moieties, which likely corresponds
to covalently attached dimers of gp120. For our subsequent
analysis of the biochemical and in vitro biological properties of
gp120-TLR7/8 conjugates, we chose to use the conjugates deﬁned
by the gel analysis containing approximately 14 linkers per gp120
(designated gp120-Lo) and 21 linkers per gp120 (designated
gp120-Hi). Because of the heterogeneity of the gp120:cross-linker
reaction products, and because previously we had observed that
during crystallization trials deglycosylation of gp120 by PNGase
would result in aggregation to higher molecular weight species
(not shown), we did not to attempt conﬁrmation of the gp120:
cross-linker stoichiometry by mass spectroscopy.
To achieve a homologous population of monomers for the
biological analysis, and to remove unreacted TLR7/8 ligand, we
subjected the reaction products to size exclusion chromatography
(SEC). As expected, gp120, gp120-Lo and gp120-Hi were resolved
by SEC in a manner consistent with their relative MW estimated
Y. Feng et al. / Virology 446 (2013) 56–65 59in parallel by the SDS-PAGE analysis (Fig. 2 and not shown). Pure
monomers were isolated by excluding the ﬁrst 25% of the elution
peak for each ligand-protein conjugate. Additional peaks were
detected after resolution of the main gp120-conjugate peaks.
Since, such peaks were not detected when unconjugated gp120
was subjected to the same SEC analysis it is likely that the peaks
were not contaminants in the gp120 preparation and represented
elution of non-gp120-bound forms of the TLR7/8 ligand in differ-
ent aggregation states. After subsequent buffer exchange by
dialysis into PBS, using a 30 kDa cut-off to remove potential trace
amounts of free TLR7/8 ligand, we conﬁrmed the homogeneity of
gp120, gp120-Lo and gp120-Hi by gel electrophoretic analysis
(Fig. 2D).In vitro stimulation of primary human DC subsets
with the gp120-TLR7/8 conjugates
To analyze the biological activity of the gp120-TLR7/8 Hi and Lo
conjugates on primary human DCs, we used a sorting procedure
for isolation of CD11c+ MDCs and CD123+ PDCs, directly from
blood. This protocol results in highly pure populations of viable
MDCs and PDCs (Fig. 3A). We have previously characterized the
stimulatory effects of TLR ligands on these DC subsets as well as
their capacity to act as antigen-presenting cells (Lore et al., 2003).
These and other studies show that MDCs produce IL-12 in
response to TLR3 and TLR7/8 ligation and are potent antigen-
presenting cells, while PDCs produce high levels of IFN-alpha in
response to TLR9 and TLR7/8 stimulation, which in turn can
impact B cell activation and differentiation in co-culture systems
(Bekeredjian-Ding et al., 2005; Douagi et al., 2009), but are less
efﬁcient as antigen-presenting cells.
Here, we stimulated MDCs and PDCs for 24 h with unconju-
gated gp120, gp120-Lo or gp120-Hi. Secreted IL-12 and IFN-alpha
were analyzed by ELISA from MDC or PDC supernatants, respec-
tively. We found that incubation of MDCs with either gp120-Lo or
gp120-Hi resulted in IL-12 production with an increase of approxi-
mately 3-fold for gp120-Lo and 2-fold for gp120-Hi when the
concentration of protein was raised from 10 mg/ml to 25 mg/ml
(Fig. 3B). No detectable IL-12 was measured from MDC cultures
stimulated with the unconjugated gp120 control protein. In con-
trast, for PDCs, only the gp120-Hi conjugate, at concentrations ofFig. 3. Purity of human PDCs and MDCs and in vitro stimulation with gp120 conjuga
bead positive selection (AutoMacs, Miltenyi Biotec) using BDCA-4 followed by CD1c DC
MDCs and pDCs, respectively. PDCs and MDCs cultured at 1106 cells/ml in 0.2 ml in
Secreted IL-12p40+p70 and IFN-alpha from stimulated MDCs and PDCs, respectively, w
donors are shown. (B) MDCs and PDCs were stimulated for 24 h with 25 μg/ml gp120
compared to that in unstimulated control cultures (gray, ﬁlled histograms).25 or 50 mg/ml induced IFN-alpha at detectable levels. From these
in vitro data, we conclude that the more biologically active
conjugate was the gp120-Hi TLR7/8 derivative which thereby
became the more critical conjugate to evaluate by further analysis.Antigenic characterization of conjugate proteins
A critical event to activate the humoral immune response by
vaccine antigens is the recognition of surface exposed antigenic
surfaces by the naïve B cell receptor (BCR). This subsequently leads
to the maturation of the humoral immune response and the
elicitation of high-afﬁnity antibodies against all immunogenic
sites on the antigen. While the covalent attachment of TLR ligands
to an antigen may lead to a more effective activation of the innate
immune response through TLRs expressed by immune cells, such
coupling may adversely alter the antigenic surface of the target
protein. The alteration of the antigenic surface could misdirect B
cell afﬁnity maturation to an altered epitope, thereby ablating of B
cell responses directed toward neutralizing Ab epitopes. Therefore
we sought to determine whether the initial coupling reaction with
the NHS-maleimide linker interfered with the recognition of
important antigenic surfaces on gp120.
We initially assessed the antigenic preservation of the highly
conserved CD4bs and the co-receptor binding site (CoRbs) of Env
using antibody probes. The naïve BCR generally has a relatively
low afﬁnity (μM) for its cognate binding surface, in contrast to a
mature Ab, which can possess extremely high afﬁnity for the same
antigenic surface. To investigate Ab recognition of the CD4 binding
region of gp120, we probed this surface with the high-afﬁnity,
broadly neutralizing CD4bs-directed monoclonal Abs (mAbs)
VRC01 and PGV04 (Fig. 4). We also included the less broadly
neutralizing CD4bs-directed mAbs, b12, HJ16, the non non-broad
F105 and b6 mAbs, as well as the co-receptor binding site (coRbs)-
directed mAb 17b with or without pre-incubation with soluble
CD4 (sCD4). This analysis demonstrated that conjugation affected
the recognition of gp120 by both broad and non-broad CD4bs-
directed mAbs, as well as of the CoRbs-directed 17b mAb. These
effects were especially pronounced at the higher coupling ratio
(Fig. 4). For example, the 50% binding concentration (BC50) of
VRC01 to wt gp120 was 0.0094 mg/ml while binding at the low
conjugation concentration (gp120-Lo) was 0.0351 mg/ml and at thetes. (A) Primary DCs were isolated from elutriated monocytes by immunomagnetic
isolation kits (Miltenyi Biotec). The purities of the populations were 98 and 97% for
round bottom tubes were stimulated for 24 h with gp120, gp120-Lo or gp120-Hi.
ere measured in the supernatants by ELISA. Representative data from one of three
-Hi (black, unﬁlled histogram) and the surface expression of CD83 and CD40 was
Fig. 4. The antigenic surface of gp120 probed with monoclonal antibodies to the
receptor binding sites before and after coupling with cross-linker. Binding curves
for the broadly neutralizing CD4bs-directed mAbs VRC01, PGV04 and the less broad
b12, HJ16, b6 and F105 CD4bs-directed antibodies. 17b is directed against the
CoRbs. The V3-speciﬁc 447-52D, glycan-speciﬁc 2G12 mAbs, which do not possess
lysines in their epitopes, and HIVIG, consisting of pooled polyclonal sera from HIV-
infected individuals, served as controls to ensure that similar amounts of protein
were analyzed by ELISA before and after cross-linking. The results are representa-
tive of two independent experiments.
Fig. 5. The gp120 molecular surface after modiﬁcation of selected lysines to
arginines and antigenic analysis of the conjugates. (A) The gp120 core is shown
with the lysines near the VRC01 epitope (left, yellow) or CD4bs (right, yellow)
highlighted in burnt orange. These ﬁve lysine residues were altered to arginine
(gp120 core 5K/R) by genetic means. These conservative changes did not affect the
electrostatic surface as shown in (B). (C) Recognition by a subset of the CD4bs-
directed mAbs and CD4-Ig by ELISA of unmodiﬁed gp120 and the gp1205K/R
variant at Hi and Lo coupling ratios. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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Table. S1). The effect of the conjugation was not global as binding
of 447-52D, an Ab speciﬁc for the third major variable region (V3)
and 2G12, an Ab speciﬁc for a highly conserved cluster of highmannose glycans on the outer domain of gp120, were not affected.
Furthermore, neither of these structurally deﬁned Abs possess a
lysine residue in their epitope. Collectively this analysis demonstrates
that covalent coupling of ligands to gp120 using the approach
Y. Feng et al. / Virology 446 (2013) 56–65 61described here severely compromises the recognition of important
epitopes by the humoral immune system.Structure guided lysine-to-arginine substitution proximal
to the CD4 binding site
Due to the loss of recognition of the CD4 binding site by the
broadly neutralizing mAbs, we inspected the gp120 molecular
surface from the available gp120 core crystal structure to perform
conservative substitutions of CD4bs-proximal lysine (K) residues
to arginine (R). As shown in Fig. 5A, we selected 5 K residues most
proximal to the composite footprint of the CD4bs broadly neu-
tralizing ligands and CD4 itself and introduced substitutions to R
(termed gp120 K/R). These conservative substitutions would
render these residues non-reactive with the cross linker and also
should not alter the electrostatic surface of gp120 as determined
by modeling (Fig. 5B). Therefore, electrostatic changes should not
be a factor altering the protein biochemically. Following produc-
tion and puriﬁcation of the 5Kgp120R variant, we performed the
lysine-speciﬁc reactions again using the NHS-maleimide linker
adduct at the low and high conditions. Following conjugation, we
performed ELISAs as before with the set of six mAbs. As shown in
Fig. 5C, even with the 5 K to R substitutions there was still a modest
loss of recognition by the CD4bs mAbs and CD4-Ig under the 20:1
linker:gp120 reaction conditions and a greater loss of recognition
under the higher 120:1 linker: gp120 reaction conditions.Fig. 6. Binding kinetics of mAbs to unmodiﬁed and cross-linker conjugated gp120.
Shown in blue are the binding curves of VRC01, F105 and 447-52D to representative prep
800 nM, 200 nM, 50 nM, 12.5 nM, 3.13 nM and 0.78 nM respectively (highest concentratio
binding kinetics (seconds (s), minutes (M) and non-detectable binding (ND)). KD, Kon and
Layer Interferometry (ForteBio). The data are representative of three independent experi
is referred to the web version of this article.)Binding kinetics of antibodies to gp120-conjugates following coupling
Since we saw decreases in recognition of the gp120-conjugates
by ELISA relative to unmodiﬁed gp120, we sought to determine
binding kinetics to determine one-to-one changes in afﬁnity
rather than the avidity changes determined by ELISA using
bivalent IgG. Therefore, we attached selected antibodies to the
solid phase and determined kinetics to monomeric gp120 and to
cross-linker conjugated gp120 in solution by Bio-Layer Interfero-
metry (FortéBio). As shown in Fig. 6, on-rates of all antibodies
were slightly reduced at the Lo conjugation conditions. By this
more direct assessment of afﬁnity, effects on the on-rate, even for
447-52D at the Lo conditions were detectable. The 447-52D mAb
recognizes a continuous epitope in the V3 region of gp120.
However, at the Hi conditions, the on-rates of all the antibodies
were affected. Most critically, for the broadly neutralizing CD4bs
there was almost no detectable binding for CD4bs-directed mAbs
VRC01 and F105. The off-rate of 447-52D was not greatly affected
under either of the conjugation conditions, implying that for this
Ab and epitope, the results are consistent with steric occlusion
caused by the cross-linker. This occlusion apparently is manifest
with less than full occupancy of the surface lysines, which are not
directly part of the 447-52D epitope. For the CD4bs-directed Abs,
the data do not clearly distinguish between steric occlusion
imposed by the cross-linker coupling or by more direct effects
on the conformational CD4bs epitopes recognized by VRC01
and F105.Unmodiﬁed and cross-linker conjugated gp120 were used for the kinetics analysis.
arations of gp120, gp120-Lo and gp120-Hi glycoproteins at various concentrations of
ns, top to bottom). Red curves depict the theoretical Langmuir ﬁts generated by 1:1
Koff values are shown for which there was detectable binding as determined by Bio-
ments. (For interpretation of the references to color in this ﬁgure legend, the reader
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TLR ligands are small bioactive molecules known to act as
immune-enhancers and/or immune-modulators in a variety of
contexts. The in vivo effect of co-administering TLR ligands and
protein antigens in the absence of conjugation or formulation may
be limited due to diffusion of the small agonists from the site of
injection (Wille-Reece et al., 2006). However, addition of TLR
ligands to vaccines containing MF59 or Alum, two adjuvants in
clinical use, markedly affects the quality and sometimes the
magnitude of the induced response (Baldwin et al., 2012; Cooper
et al., 2004a, 2004b; Crompton et al., 2009; Mullen et al., 2006;
Wack et al., 2008). In some settings the inclusion of a TLR ligand in
the formulation skews the response toward a Th1-type of response
or shifts it toward a balanced Th1/Th2 type of response, which
may be more desirable than a predominant Th2-biased response
such as that elicited by alum alone. The more balanced response
afforded by inclusion of TLR ligands may increase the effectiveness
of vaccine-induced immune responses against many pathogens,
including HIV-1 (Baldwin et al., 2012; Darrah et al., 2007; Lousada-
Dietrich et al., 2011; Pattacini et al., 2012).
To evaluate an alternative approach to harness the potent
biological activity of TLR ligands, we directly coupled a TLR7/8
ligand to gp120 by targeting the secondary amines typically found
on solvent exposed lysine residues. The possibility to covalently
couple TLR ligands to protein antigens is advantageous in that it
diminishes systemic dissemination of the ligand upon inoculation,
which might cause bystander effects. Covalent coupling also
greatly increases the likelihood that the antigen and adjuvant
are taken up by the same antigen-presenting cell, which may
enhance antigen presentation to CD4+ T cells (Blander and
Medzhitov, 2006). An early study evaluated the effect of direct
conjugation of the TLR9 ligand to HIV-1 gp120 and found that
coupling resulted in improved immunogenicity of gp120, however
a detailed examination of the antigenic properties of the gp120-
CpG conjugates was not performed in that study (Tighe et al.,
2000). Here, we used a TLR7/8 ligand for covalent coupling to
gp120 as, in addition to stimulating MDCs and PDCs, TLR7/8
ligands are potent polyclonal B cell stimulators (Douagi et al.,
2009; Ruprecht and Lanznvecchia, 2006).
Chemical conjugation of TLR7/8 or TLR9 ligands to HIV-1 Gag,
a T cell antigen, was previously shown to increase the immuno-
genicity of this protein antigen (Wille-Reece et al., 2005a, 2005b).
Subsequent studies showed that conjugation to the antigen was
also critical for effective cross-presentation to CD8+ T cells (Oh
and Kedl, 2010). However, a potential draw-back when coupling
ligands to proteins is that the antigenic surface of the protein
may be altered, either by direct disruption of speciﬁc B cell
epitopes, or by steric effects imposed by the hetero-bifunctional
cross-linkers used for coupling. Coupling, as performed here, is
often done by lysine-directed chemistry. Furthermore, depending
on the biochemical properties of the protein and the coupling
chemistry used, the process may result in protein aggregation
and subsequent disruption of epitope recognition (Kastenmuller
et al., 2011). Aggregation may be less critical for immunogens
aimed to elicit potent T cell responses, and might even enhance
processing and cross-presentation of peptides to CD8+ T cells,
but for B cell immunogens aimed to elicit bNAbs aggregation is
best avoided. For gp120 this is especially pertinent as many
broadly neutralizing anti-gp120 Abs recognize relatively poorly
exposed, conformation-sensitive epitopes, which contain lysines
near or within their binding footprint. Thus, preservation of the
integrity of these epitopes is likely critical for the elicitation and
antigen drive of CD4bs-directed B cell responses that would
afﬁnity mature to this region and be capable of neutralizing
HIV-1.Here, we show that the effective coupling of the TLR7/8 ligand
to the heavily glycosylated gp120 was achievable, rendering it
more immune activating compared to unconjugated gp120 when
assessed on primary human DCs, in vitro. By our estimates of
cross-linker units coupled to lysines on gp120 we observed that
the coupling process did not go to completion, especially under
the lower ratios of cross-linker to gp120. Even at the highest ratio,
which was in vast molar excess of cross-linker to gp120, approxi-
mately two thirds of the surface lysines were conjugated. This
relative inefﬁciency reﬂects the challenges of subjecting a complex
carbohydrate-laden glycoprotein such as gp120 to this coupling
approach.
In the studies presented here, we attached a heterobifunctional
cross-linker to gp120 surface lysines and we estimated cross-
linker occupancy on the heavily glycosylated gp120 by a combina-
tion of PNGase deglycosylation and SDS gel analysis. We had
observed previously during crystallization trials that the use of
PNGase to deglycosylate gp120 resulted in aggregation of gp120 to
higher molecular weight species. We therefore did not attempt to
determine gp120:cross-linker stoichiometry by mass spectro-
scopy of the PNGase treated products, but instead relied on the
analysis of MW shifts as determined by the gel analysis. We found
that the cross-linker conjugation process severely affected recog-
nition by several bNAbs, illustrating the potential limits of
this direct coupling approach for the generation of effective B cell
immunogens.
For the CD4bs mAbs, not all footprints are structurally deﬁned,
but for those that are, proximity of lysines to this critical neu-
tralizing determinant was a concern for linker-mediated ligand
coupling. Indeed, following the cross-linker conjugation proce-
dure, reduction in recognition of the CD4bs was observed for most
antibodies directed to this region. Although some of reductions in
afﬁnity resulted in reasonable afﬁnities of the mature CD4bs mAbs
to gp120, decreases in afﬁnity are indicative of an altered CD4bs or
partial steric occlusion of this region. Alterations in optimal B cell
recognition will alter afﬁnity maturation pathways, and are likely
to impact on the elicitation of optimal antibodies to the CD4bs due
to the cross-linking. Effects on antibody binding to gp120 by
addition of multiple cross-linkers may not be so surprising, as
the cross-linkers are 40 Å in length and core gp120 is only 100 Å
across in several orientations. So although the cross-linkers do not
greatly increase the overall mass of gp120, their presence, along
with the abundant N-linked glycans on the surface of gp120, may
occlude multiple antigenic sites.
Due to the effects of the cross-linker on antibody recognition at
the CD4bs, we performed conservative arginine shifts to eliminate
coupling to lysines proximal to this site. However, this did not
circumvent loss of antigenic recognition by CD4bs-directed ligands
or by the CoRbs-directed ligand, 17b. The coupling-dependent
decrease in recognition by 17b under all conditions was consistent
with its structurally deﬁned footprint, which is known to contain
several unmodiﬁed lysine residues. That arginine substitution did
not alter loss of recognition by the CD4bs-directed bNabs follow-
ing coupling was somewhat unexpected. This result might be due
to distal conformational effects caused by the cross-linker or by
steric interference with recognition of the CD4bs. That CD4
requires a conformational change for high afﬁnity binding and
that CD4-Ig was markedly affected following cross-linker coupling
suggests that the former explanation might partially account for
the observed effects. To assess the latter possibility, we also
performed coupling using a cross-linker (PEO2) possessing a
shorter backbone linker length, but we found that the shorter
linker also altered recognition of ligands to the CD4 binding site
(not shown). The binding kinetics indicated steric occlusion might
be responsible for the observed decrease in recognition by the
V3-directed antibody 447-52D, but this analysis was less deﬁnitive
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These data suggest that other direct or indirect linker strategies
might be considered when coupling TLR ligands to proteins
possessing critical and conformational immune determinants.
In sum, we show efﬁcient TLR ligand conjugation to gp120 that
enhanced the capacity of the antigen to stimulate primary DC
subsets resulted in a marked loss of Ab recognition of broadly
reactive B cell epitopes on HIV-1 Env. These results reveal a
limitation to this conjugation approach, which should be taken
into consideration in future Env vaccine design efforts.Materials and methods
Recombinant gp120 production and site-directed mutagenesis
Adhesive 293F cells (ATCC), in the presence or absence of 20 μg/
L swainsonine, were transiently transfected, using 293 Fectin™,
with a pcDNA3.1 plasmid encoding gp120 according to the
manufacturer′s instructions (Invitrogen, Life Sciences). After four
days, the cell media was harvested, cleared of cells by centrifuga-
tion and ﬁltered through a 0.2 μm ﬁlter. Recombinant gp120 was
then puriﬁed by 17b-afﬁnity chromatography, concentrated with
an Amicon spin column and dialysed against a buffer containing
PBS, 0.3 M NaCl and 5 mM EDTA at pH 7.1. Non-conjugated and
conjugated gp120 were deglycosylated with PNGase (New England
BioLabs) at 37 1C. In some experiments we used GnTI- 293S cells
(ATCC) for production of gp120 containing Man5 N-linked glycans.
To eliminate the reaction of cross-linker with lysine residues
proximal to or within the composite footprint of the CD4bs mAbs
and CD4 itself, 5 lysine (K) codons at positions 121, 282, 357, 421
and 432, respectively were altered to Arginine (R) codons by
QuikChange Mutagenesis (Stratagene). The gp1205K/R mutant
was expressed and puriﬁed as described above for subsequent
analysis.
Covalent coupling of TLR7/8 ligand to YU2 gp120
The imidazoquinoline compound (3M-012) referred to as the
TLR7/8 ligand modiﬁed to contain an SH group was provided by 3M
Pharmaceuticals. The contaminating endotoxin levels were
≤0.125 EU/ml in the TLR ligand preparations as measured using a
Limulus Amebocyte Lysate assay, in which 10 EU equals approxi-
mately 1 ng endotoxin. The TLR7/8 ligand was covalently linked to
gp120 in PBS containing 0.3 M NaCl and 5 mM EDTA at pH 7.1 in a
two-step process. First, puriﬁed gp120 was reacted with a DMSO-
dissolved cross-linker at various molecular ratios for 1 h. The linker
contains a primary amine-reactive N-hydroxysuccinimide ester
(NHS) group, which reacts with surface-exposed lysines and the
N-terminus on gp120, a polyethylene oxide8 (PEO8¼polyethylene
glycol) and a thiol-reactive maleimide group (Pierce). Excess linker
was removed by a PD-10 column (GE-Healthcare). The maleimide
group of the gp120-PEO8-maleimide intermediate was then reacted
with the thiol group on the TLR7/8 ligand, at a 4-fold molar excess,
for 1 h. To quench the reaction, 100 mM free L-Cys was added and the
gp120-TLR7/8 conjugates were puriﬁed with a superdex 200 10/
500GL gel ﬁltration column using an ÄKTA system. Aliquots of the
intermediate gp120-linker product were retained for analysis. In
some experiments, we coupled gp120 using a PEO2 cross-linker by
similar methods (not shown).
Quantiﬁcation of cross-linker attachment to gp120
The migration pattern of the different known MW bands of a
PreSieves protein ladder (Lonz Rockland, Inc.) on an reducing
SDS-page gel was used to approximate an equation describing thelog MW of a protein as a function of its relative migration distance
(Rf) by using linear curve-ﬁt in Prism 5 (y¼0.8803ln(x)+2.411,
r2¼0.97). Since gp120 is a relatively large, heavily glycosylated
protein, with N-linked carbohydrate comprising roughly 50% of its
molecular mass, we reasoned that deglycosylated gp120 might
enable us to better estimate the apparent MW. The non-
conjugated and conjugated gp120 were treated with PNGase F
(New England Biolabs, Inc.) according to the manufacturer′s
instructions. In brief, samples were denatured in the Glycoprotein
Denaturing Buffer at 100 1C for 10 min. Deglycosylation was then
performed by incubating the protein in Reaction Buffer at 37 1C for
1 h in the presence of PNGase F. The amount of linker attached to
each gp120 under different conditions was estimated by subjecting
deglycosylated gp120-(PEO8)X to gel electrophoresis under reducing
conditions. The PNGase F protein band in each lane on the gel also
served as an internal reference to normalize the migration of the
gp120 in different lanes. Each covalently attached PEO8 accounts for
an approximate 0.69 kDa increase in MW when compared to non-
conjugated gp120. From the increase in kDa, the approximate cross-
linker stoichiometry per gp120 was determined.
Env antigenicity analysis by ELISA
The following antibodies were kindly obtained from James
Robinson (17b), Susan Zolla-Pazner (447-52D), Marshal Posner
(F105), Dennis Burton (b6 and b12), Herman Katinger (2G12),
Davide Corte (HJ16) and HIVIG (the NIH AIDS Reagent Program).
High-protein-binding MaxiSorp plates (Nunc) were coated with
200 ng/well of lentil lectin in 100 μl PBS at 4 1C overnight and then
blocked with PBS-2% fat-free milk for 2 h at room temperature.
After washing by PBS, 200 ng/well of gp120 or gp120-(PEO8)X was
added into plate and incubated for 1 h. The plate was then probed
with mAbs VRC01, PGV04, HJ16, b6, 447-52D, 2G12, b12, F105, 17b
(7soluble CD4, sCD4) or CD4-Ig for 1 h and subsequently washed
in PBS, containing 0.05% Tween. Addition of HRP-conjugated anti-
human-Ig (Jackson) followed by the colorimetric peroxide enzyme
immunoassay substrate (3,3′,5,5′-tetramethylbenzidine; Bio-Rad)
was used to induce a colorimetric change, based on the level of
mAb:gp120 complexes in each well, and the reaction was stopped
by adding 1 M H2SO4. OD was read at 450 nm.
Isolation and stimulation of primary human dendritic cell subsets
This study was approved by the Institutional Review Boards at the
NIH and Karolinska Institutet. Our sorting procedures for direct
isolation of subsets of DCs from peripheral blood mononuclear cells
(PBMCs) have been described previously (Douagi et al., 2009; Lore
et al., 2003). Brieﬂy, PDCs and MDCs were isolated from elutriated
monocytes using the BDCA-4 and the CD1c DC isolation kits,
respectively (Miltenyi Biotec). Following this puriﬁcation, the subsets
of DCs were highly enriched (on average 490% PDCs and 480%
MDCs) as determined by staining for the Lineage markers CD3, CD14,
CD15, CD20 and CD56 plus HLA-DR, CD123 and CD11c. DCs were
cultured in complete medium (RPMI 1640 (BioWhittaker, Inc., Walk-
ersville, MD) supplemented with 2 mmol/l L-glutamine, 1% strepto-
mycin and penicillin, 10% FCS (Invitrogen, Carlsbad, CA). To maintain
viability, the media for PDCs and MDCs were supplemented with the
recombinant human cytokines IL-3 (1 ng/ml, R&D Systems, Minnea-
polis, MN) and GM-CSF (2 ng/ml, PeproTech Inc, Rocky Hill, NJ),
respectively. The sorted DC populations were cultured at
1106 cells/ml at 37 1C in polystyrene round-bottom tubes
(Becton Dickinson Labware, Franklin Lakes, NJ). The DCs were
stimulated with unconjugated gp120, gp120-Lo and gp120-Hi (10,
25 or 50 μg/ml) as indicated for 24 h and the supernatants were
analysed for secretion of IFN-alpha and IL-12 (p40 and p70) ELISA.
Both ELISA kits were purchased from (Biosource International,
Y. Feng et al. / Virology 446 (2013) 56–6564Camarillo, CA) and the assays were performed according to the
manufacturer′s instructions.
Binding kinetics by bio-layer Interferometry
Experiments were performed on the Octet-Reds device
(FortéBio, Inc., Menlo Park, CA). Buffer or serially diluted samples
of gp120 or conjugates were dispensed into 96-well microtiter
plates at a volume of 200 μl per well. Operating temperature was
maintained at 30 1C. Anti-Human IgG Fc biosensors (FortéBio, Inc.,
Menlo Park, CA) were used to capture VRC01, F105 or 447-52D
antibodies which were then dipped into solutions of the gp120 or
conjugates at selected concentrations with agitation for 6 min at
1000 rpm to measure association constants. Dissociation was
detected following transfer of sensors into wells containing buffer
alone for 6 min. Data were collected and analyzed by the Octets
User Software (version 6.4). For data analysis, different concentra-
tion ranges were used: 800 nM, 200 nM, 50 nM and 13 nM for
gp120-Hi binding with VRC01 and F105, gp120-Lo binding with
VRC01 and F105; 800 nM, 200 nM and 50 nM for gp120-Hi
binding with 447-52D; 200 nM, 50 nM, 13 nM and 3 nM for
gp120-Lo binding with 447-52D and gp120 binding with VRC01;
50 nM, 13 nM, 3 nM and 0.78 nM for gp120 binding with F105 and
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